Continuous Ambulatory Cardiac Monitoring for Recurrent Atrial Fibrillation After Sepsis (CAMS-AF)

NHS Foundation Trust

Status: Unknown

Conditions: Atrial Fibrillation; Cardiac Arrhythmia; Infections; Sepsis

Treatments: Device: Zio 14-day cardiac patch

Study type: Interventional

Funder types: Other

Identifiers

NCT05217485

CAMSAF

Details and patient eligibility

About

To detect atrial fibrillation after infection.

Full description

This study will prospectively recruit patients who are admitted to CUH general medical wards due to an infection or sepsis and develop new/first diagnosed transient AF. In CUH, our previous projects have shown that around 1500 patients are admitted under general medicine each month at least 1 new diagnosis of AF is made each day (30/month)26.

In particular to the cohort that develop sepsis, they may well be frail and elderly where anticoagulation is often not prescribed as a result 27 unless definitive diagnosis of recurrent AF would be made. The CAMS-AF study will closely tie in with an already existing stroke prevention service at CUH (SOS-AF) who are already screening for patient admitted with AF on general medical wards and will therefore be able to identify those with new AF during an episode of sepsis. Potential participants will be approached by the study investigators prior to discharge and if they are in sinus rhythm written consent will be obtained to place a non-invasive wearable cardiac monitor patch for 14-days, to detect any subclinical arrhythmias, particularly AF.

Enrollment: 125 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age >18
• Admission with any infection or sepsis
• Transient AF
• Under general medicine
• Can be anticoagulated or not
• Sinus rhythm at discharge or point of Zio patch placement

Exclusion criteria

• Previous history of AF or paroxysmal AF
• Age less than 18 years
• Pregnancy
• Active and known malignancy
• Recent cardiac or non-cardiac surgery (3 months)
• Recent myocardial infarction (3 months)
• Individuals with skin allergies to plasters and adhesive devices
• Chest wall deformity, skin condition over sticker site
• History of thyroid disease
• Current alcohol intake above recommended limits
• Already has a cardiac monitor or pacemaker inserted
• Known contraindication for anticoagulation therapy
• Patients who lack capacity or have an estimated life expectancy < 1 year

Trial design

Primary purpose: Diagnostic

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

125 participants in 1 patient group

Infection and reverted atrial fibrillation

Experimental group

Description:

Patients who have developed first-diagnosed atrial fibrillaiton in the context of sepsis or infection

Treatment:

Device: Zio 14-day cardiac patch